Core Viewpoint - Ascentage Pharma-B (06855) announced key appointments to its board, including the establishment of a new R&D committee, effective December 26, 2025 [1] Group 1: Board Appointments - Dr. Debra Yu will be appointed as a new member of the Board Nomination Committee, effective December 26, 2025 [1] - Dr. David Sidransky will be appointed as the Chief Independent Non-Executive Director, effective December 26, 2025, to act as an intermediary between other directors and the company's shareholders, and to communicate with other directors and shareholders when normal communication channels with the board chair or management are insufficient [1] Group 2: R&D Committee Establishment - The R&D Committee will be established, effective December 26, 2025, consisting of scientists, physicians, and business experts responsible for overseeing R&D strategies, product lines, investments, and emerging trends while managing risks and ensuring alignment with business objectives [1] - Dr. Marc E. Lippman will serve as the chair of the R&D Committee, with Dr. David Sidransky and Dr. Wang Shaomeng as members [1]
亚盛医药-B(06855)：David Sidransky将获委任为首席独立非执行董事